JP2019196370A5 - - Google Patents

Download PDF

Info

Publication number: JP2019196370A5
Authority: JP; Japan
Prior art keywords: peptide; use according; effective amount; therapeutically effective; ranges
Prior art date: 2019-07-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2019124501A

Other languages

English (en)

Japanese (ja)

Other versions

JP2019196370A (ja

Filing date

2019-07-03

Publication date

2020-02-20

2019-07-03 Application filed filed Critical

2019-11-14 Publication of JP2019196370A publication Critical patent/JP2019196370A/ja

2020-02-20 Publication of JP2019196370A5 publication Critical patent/JP2019196370A5/ja

2021-11-04 Priority to JP2021179961A priority Critical patent/JP2022023208A/ja

Status Pending legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 claims 16
108050003475 Neuregulin Proteins 0.000 claims 8
102000014413 Neuregulin Human genes 0.000 claims 8
241000124008 Mammalia Species 0.000 claims 4
206010019280 Heart failures Diseases 0.000 claims 2
238000002347 injection Methods 0.000 claims 2
239000007924 injection Substances 0.000 claims 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
108050002150 EGF-like domains Proteins 0.000 claims 1
102000012545 EGF-like domains Human genes 0.000 claims 1
101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 claims 1
239000012634 fragment Substances 0.000 claims 1
230000010005 growth-factor like effect Effects 0.000 claims 1
102000055650 human NRG1 Human genes 0.000 claims 1
238000001990 intravenous administration Methods 0.000 claims 1
238000010253 intravenous injection Methods 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 claims 1
238000007920 subcutaneous administration Methods 0.000 claims 1
238000010254 subcutaneous injection Methods 0.000 claims 1
239000007929 subcutaneous injection Substances 0.000 claims 1

JP2019124501A 2008-07-17 2019-07-03 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法 Pending JP2019196370A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2021179961A JP2022023208A (ja)	2008-07-17	2021-11-04	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13517108P	2008-07-17	2008-07-17
US61/135,171		2008-07-17

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2017150365A Division JP2017200949A (ja)	2008-07-17	2017-08-03	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2021179961A Division JP2022023208A (ja)	2008-07-17	2021-11-04	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法

Publications (2)

Publication Number	Publication Date
JP2019196370A JP2019196370A (ja)	2019-11-14
JP2019196370A5 true JP2019196370A5 (2)	2020-02-20

Family

ID=42005671

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
JP2011518734A Expired - Fee Related JP5797112B2 (ja)	2008-07-17	2009-07-17	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2015013248A Expired - Fee Related JP6189879B2 (ja)	2008-07-17	2015-01-27	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2017150365A Pending JP2017200949A (ja)	2008-07-17	2017-08-03	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2019124501A Pending JP2019196370A (ja)	2008-07-17	2019-07-03	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2021179961A Pending JP2022023208A (ja)	2008-07-17	2021-11-04	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
JP2011518734A Expired - Fee Related JP5797112B2 (ja)	2008-07-17	2009-07-17	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2015013248A Expired - Fee Related JP6189879B2 (ja)	2008-07-17	2015-01-27	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
JP2017150365A Pending JP2017200949A (ja)	2008-07-17	2017-08-03	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2021179961A Pending JP2022023208A (ja)	2008-07-17	2021-11-04	心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法

Country Status (13)

Country	Link
US (5)	US20110166068A1 (2)
EP (3)	EP3338791B1 (2)
JP (5)	JP5797112B2 (2)
CN (3)	CN107019794B (2)
AU (3)	AU2009292216B2 (2)
BR (1)	BRPI0916442A2 (2)
CA (1)	CA2731113A1 (2)
DK (2)	DK2320933T3 (2)
ES (2)	ES2763184T3 (2)
MX (2)	MX384378B (2)
PL (2)	PL3338791T3 (2)
RU (4)	RU2536938C2 (2)
WO (1)	WO2010030317A2 (2)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20110166068A1 (en) *	2008-07-17	2011-07-07	Acorda Therapeutics, Inc.	Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
EP3777878A1 (en)	2008-08-15	2021-02-17	Acorda Therapeutics, Inc.	Compositions and methods for treatment during non-acute periods following cns neurological injury
EP2370458B1 (en) *	2008-11-28	2014-10-15	Zensun (Shanghai) Science and Technology Limited	Neuregulin peptides and their use
NZ625673A (en)	2009-10-14	2015-11-27	Acorda Therapeutics Inc	Use of a neuregulin to treat peripheral nerve injury
WO2013053076A1 (en) *	2011-10-10	2013-04-18	Zensun （Shanghai）Science & Technology Limited	Compositions and methods for treating heart failure
EP3842059A1 (en) *	2012-03-30	2021-06-30	Acorda Therapeutics, Inc.	Ggf2 to treat surgical peripheral nerve injury or neuropathic pain therefrom
JP6542678B2 (ja) *	2013-03-06	2019-07-10	アコーダセラピューティクスインコーポレイテッド	心不全の治療または予防のためのニューレグリンまたはその断片の治療的投与の方法
EP3895724B1 (en)	2013-05-22	2025-06-25	Zensun (Shanghai) Science and Technology, Co., Ltd.	Extended release of neuregulin for treating heart failure
CN110946993A (zh)	2014-01-03	2020-04-03	上海泽生科技开发股份有限公司	纽兰格林制剂的配方
CN111407882A (zh) *	2014-10-17	2020-07-14	上海泽生科技开发股份有限公司	神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
WO2017053794A1 (en)	2015-09-25	2017-03-30	Sawyer Douglas B	Methods for treating cardiac injury
WO2017182500A1 (en) *	2016-04-19	2017-10-26	Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli)	Neuregulin for the treatment and/or prevention of tumors of the nervous system
CN110835368A (zh) *	2018-08-15	2020-02-25	上海泽生科技开发股份有限公司	神经调节蛋白多肽片段及其用途
AR121035A1 (es)	2019-04-01	2022-04-13	Lilly Co Eli	Compuestos de neuregulina-4 y métodos de uso
JP2022547335A (ja) *	2019-09-16	2022-11-11	ゼンサン（シャンハイ）サイエンスアンドテクノロジー，シーオー．，エルティーディー．	組換えヒトニューレグリン誘導体及びその使用
WO2023070078A1 (en) *	2021-10-22	2023-04-27	The Research Institute At Nationwide Children's Hospital	Neuregulin for protection against respiratory viral infection and post-viral disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7115554B1 (en) *	1993-05-06	2006-10-03	Acorda Therapeutics, Inc.	Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5716930A (en)	1991-04-10	1998-02-10	Ludwig Institute For Cancer Research	Glial growth factors
US5530109A (en)	1991-04-10	1996-06-25	Ludwig Institute For Cancer Research	DNA encoding glial mitogenic factors
US6087323A (en)	1992-04-03	2000-07-11	Cambridge Neuroscience, Inc.	Use of neuregulins as modulators of cellular communication
US7037888B1 (en)	1992-04-03	2006-05-02	Acorda Therapeutics, Inc.	Methods for treating muscle diseases and disorders
US5811098A (en) *	1992-11-24	1998-09-22	Bristol-Myers Squibb Company	Antibodies to HER4, human receptor tyrosine kinase
US5912326A (en)	1995-09-08	1999-06-15	President And Fellows Of Harvard College	Cerebellum-derived growth factors
US6136558A (en) *	1997-02-10	2000-10-24	Genentech, Inc.	Heregulin variants
US6051401A (en)	1998-07-28	2000-04-18	Bayer Corporation	Methods and constructs for protein expression
PL203689B1 (pl)	1998-09-25	2009-11-30	Cubist Pharmaceuticals	Zastosowanie daptomycyny
AUPP785098A0 (en) *	1998-12-21	1999-01-21	Victor Chang Cardiac Research Institute, The	Treatment of heart disease
US6635249B1 (en) *	1999-04-23	2003-10-21	Cenes Pharmaceuticals, Inc.	Methods for treating congestive heart failure
CN1138785C (zh) *	1999-06-04	2004-02-18	周明东	生长因子神经调节蛋白及其类似物的新应用
JP2003527337A (ja)	1999-11-12	2003-09-16	エントレメッドインコーポレイテッド	抗血管新生スケジュールに基づく治療薬の投与方法
AU2001274947B2 (en)	2000-05-23	2006-08-17	Acorda Therapeutics, Inc.	Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
CU23157A1 (es) *	2001-01-03	2006-07-18	Ct Ingenieria Genetica Biotech	COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL
EP1569689A4 (en)	2002-01-18	2009-08-05	Novartis Vaccines & Diagnostic	IL2 / ANTI-HER2-ANTIBODY COMBINATION THERAPY AGAINST CANCER, which is characterized by overexpression of the HER2-RECEPTOR PROTEIN
AU2002304965A1 (en) *	2002-05-24	2003-12-12	Zensun (Shanghai) Sci-Tech.Ltd	Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
WO2006087420A2 (en) *	2005-02-18	2006-08-24	Orion Corporation	A method for treating heart failure
JP2006265244A (ja)	2005-03-23	2006-10-05	Pfizer Prod Inc	Ｃｔｌａ４抗体とホルモン治療を用いた前立腺癌の治療
US7776817B2 (en)	2005-09-02	2010-08-17	Morehouse School Of Medicine	Neuregulins for prevention and treatment of damage from acute assault on vascular and neuronal tissue and as regulators of neuronal stem cell migration
US20070213264A1 (en) *	2005-12-02	2007-09-13	Mingdong Zhou	Neuregulin variants and methods of screening and using thereof
ES2530526T3 (es) *	2005-12-30	2015-03-03	Zensun Shanghai Science And Technology Ltd	Liberación extendida de neurregulina para mejorar la función cardíaca
WO2009108390A2 (en)	2008-02-29	2009-09-03	Acorda Therapeutics, Inc.	Method for achieving desired glial growth factor 2 plasma levels
US20110166068A1 (en)	2008-07-17	2011-07-07	Acorda Therapeutics, Inc.	Therapeutic Dosing of a Neuregulin or a Subsequence Thereof for Treatment or Pro-phylaxis of Heart Failure
NZ625673A (en)	2009-10-14	2015-11-27	Acorda Therapeutics Inc	Use of a neuregulin to treat peripheral nerve injury
EP2603221A4 (en)	2010-08-13	2014-02-26	Univ Georgetown	GGF2 AND METHOD FOR ITS APPLICATION
EP3842059A1 (en)	2012-03-30	2021-06-30	Acorda Therapeutics, Inc.	Ggf2 to treat surgical peripheral nerve injury or neuropathic pain therefrom

2009
- 2009-07-17 US US13/055,397 patent/US20110166068A1/en not_active Abandoned
- 2009-07-17 MX MX2015001826A patent/MX384378B/es unknown
- 2009-07-17 WO PCT/US2009/004130 patent/WO2010030317A2/en not_active Ceased
- 2009-07-17 EP EP17209369.2A patent/EP3338791B1/en active Active
- 2009-07-17 BR BRPI0916442-1A patent/BRPI0916442A2/pt not_active IP Right Cessation
- 2009-07-17 CN CN201710109733.2A patent/CN107019794B/zh not_active Expired - Fee Related
- 2009-07-17 EP EP09813336.6A patent/EP2320933B1/en not_active Not-in-force
- 2009-07-17 RU RU2011105821/10A patent/RU2536938C2/ru active
- 2009-07-17 AU AU2009292216A patent/AU2009292216B2/en not_active Ceased
- 2009-07-17 MX MX2011000696A patent/MX2011000696A/es active IP Right Grant
- 2009-07-17 ES ES17209369T patent/ES2763184T3/es active Active
- 2009-07-17 JP JP2011518734A patent/JP5797112B2/ja not_active Expired - Fee Related
- 2009-07-17 DK DK09813336.6T patent/DK2320933T3/en active
- 2009-07-17 PL PL17209369T patent/PL3338791T3/pl unknown
- 2009-07-17 EP EP19197381.7A patent/EP3632459A1/en not_active Withdrawn
- 2009-07-17 DK DK17209369.2T patent/DK3338791T3/da active
- 2009-07-17 CN CN2009801360798A patent/CN102159236A/zh active Pending
- 2009-07-17 CN CN201510010273.9A patent/CN104623633A/zh active Pending
- 2009-07-17 CA CA2731113A patent/CA2731113A1/en not_active Abandoned
- 2009-07-17 ES ES09813336.6T patent/ES2664394T3/es active Active
- 2009-07-17 PL PL09813336T patent/PL2320933T3/pl unknown
2013
- 2013-05-29 US US13/904,654 patent/US9198951B2/en active Active
2014
- 2014-10-14 RU RU2014141514A patent/RU2698090C2/ru active
2015
- 2015-01-27 JP JP2015013248A patent/JP6189879B2/ja not_active Expired - Fee Related
- 2015-05-27 AU AU2015202877A patent/AU2015202877B2/en not_active Ceased
- 2015-10-30 US US14/928,124 patent/US9956266B2/en active Active
2017
- 2017-05-26 AU AU2017203528A patent/AU2017203528A1/en not_active Abandoned
- 2017-08-03 JP JP2017150365A patent/JP2017200949A/ja active Pending
2018
- 2018-03-29 US US15/940,250 patent/US20180280477A1/en not_active Abandoned
2019
- 2019-07-03 JP JP2019124501A patent/JP2019196370A/ja active Pending
- 2019-08-12 RU RU2019125376A patent/RU2719199C1/ru active
- 2019-09-09 US US16/564,739 patent/US11235031B2/en not_active Expired - Fee Related
2020
- 2020-03-18 RU RU2020111236A patent/RU2020111236A/ru unknown
2021
- 2021-11-04 JP JP2021179961A patent/JP2022023208A/ja active Pending

Publication	Publication Date	Title
JP2019196370A5 (2)	2020-02-20
RU2020111236A (ru)	2021-09-21	Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
JP2016516016A5 (2)	2017-04-27
JP2022031772A5 (2)	2022-08-22
JP2015187125A5 (2)	2015-12-10
JP2016514132A5 (2)	2017-04-06
JP2012067116A5 (2)	2013-11-07
US20080213288A1 (en)	2008-09-04	Combined Use Of A Modulator Of CD3 And A GLP-1 Compound
JP2016074740A5 (2)	2016-08-18
HRP20170056T2 (hr)	2017-12-15	Terapija male učestalosti glatiramer acetatom
JP2013533858A5 (2)	2014-07-24
RU2014101207A (ru)	2015-07-20	Новые показания к применению при лечении антителами против il-1-бета
FI3356386T3 (fi)	2024-05-16	Melanokortiini-4-reseptoripolkuun liittyvien häiriöiden hoitamismenetelmä
US20250177364A1 (en)	2025-06-05	Combination therapies for breast cancer
JP2011507860A5 (2)	2013-04-25
ES2717661T3 (es)	2019-06-24	Terapia de combinación para el tratamiento de las enfermedades autoinmunes
JP2014500278A5 (2)	2015-01-29
JP2005506345A5 (2)	2006-01-05
JP2024529452A5 (2)	2025-07-30
JP2015532293A5 (ja)	2015-12-17	糖尿病患者における心不全の治療用組成物
RU2009118962A (ru)	2010-11-27	Применение антагонистов il-1 для лечения подагры и псевдоподагры
JP2022035920A5 (2)	2023-11-17
JP2020510028A5 (2)	2021-04-22
EP1450850B1 (en)	2010-09-22	Method of administering a thymosin alpha 1 peptide
JP2009538916A5 (2)	2011-05-12